WHITEHOUSE STATION, N.J.----GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine), the cervical cancer vaccine from Merck & Co., Inc., has been granted a license by the European Commission. GARDASIL has been approved as the first and only vaccine in the European Union (EU) for use in children and adolescents aged 9 to 15 years and in adult females aged 16 to 26 years for the prevention of cervical cancer, high-grade cervical dysplasias/precancers (cervical intraepithelial neoplasia [a different area of the cervix], high-grade/precancerous vulvar dysplastic lesions [precancer of the external vagina] and external genital warts caused by human papillomavirus (HPV) types 6, 11, 16 and 18. This license applies to the 25 countries that are members of the EU, including the five largest which are France, Germany, Italy, Spain and the United Kingdom.
Merck (MRK)closed up 9 cents today to finish at 42.04.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment